联系方式：400-650-8506
CNEN
产品名称 LY 2811376
产品货号 Axon 2225 CAS [1194044-20-6] MF C15H14F2N4SMW 320.36 Purity: 99% Soluble in 0.1N HCl(aq), DMSO, and Ethanol Description The first orally available non-peptidic BACE 1 inhibitor (IC50 value ranges from 239-249 nM in vitro) that produces profound Aβ-lowering effects in animals. LY2811376 demonstrated ~10-fold selectivity toward BACE 1 over BACE 2, and >50-fold selectivity over cathepsin D, pepsin, or renin. Clinical development of LY 2811376 was terminated as a result of toxicology findings identified in longer-term preclinical studies. References Certificates Categories Extra info P.C. May et al. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor. J. Neurosci. 2011, 31, 16507-16516.    Y. Lu et al. Cerebrospinal fluid amyloid-β (Aβ) as an effect biomarker for brain Aβ lowering verified by quantitative preclinical analyses. J. Pharmacol. Exp. Ther. 2012, 342, 366-375.  Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology CNS BACE-1 EC 3.4.23.46 The first orally available non-peptidic BACE 1 inhibitor Chemical name (S)-4-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine Parent CAS No. [1194044-20-6] Order Size Unit Price Stock 5 mg €125.00 In Stock
产品价格 现货询价，电话：010-67529703
产品规格
产品品牌 axonmedchem
产品概述
产品详情

LY 2811376

Based on 18 reference(s) in Google Scholar 9 10 18

Axon 2225

CAS [1194044-20-6]

MF C15H14F2N4S
MW 320.36

  • Purity: 99%
  • Soluble in 0.1N HCl(aq), DMSO, and Ethanol

LY 2811376

Description

The first orally available non-peptidic BACE 1 inhibitor (IC50 value ranges from 239-249 nM in vitro) that produces profound Aβ-lowering effects in animals. LY2811376 demonstrated ~10-fold selectivity toward BACE 1 over BACE 2, and >50-fold selectivity over cathepsin D, pepsin, or renin. Clinical development of LY 2811376 was terminated as a result of toxicology findings identified in longer-term preclinical studies.
产品资料